Synergetic effect of Azacitidine and Sorafenib in treatment of a case of myeloid neoplasm with sole chromosomal abnormality t(8;22)(p11.2;q11.2)/BCR-FGFR1 rearrangement

Chronic myeloid leukaemia (CML) occurs due to t(9;22)(q34;q11.2)/BCR/ABL fusion gene. Some group of patients with myeloproliferative neoplasm clinically presented as CML, and shows no evidence of BCR/ABL fusion [(t9;22)] gene are diagnosed as atypical chronic myeloid leukaemia [aCML][1]. Recently, the WHO classification (5th edition) of haematolymphoid tumours, classified neoplasm with FGFR1 translocation under the category of "Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions ” [2].
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research